Veru Inc (VERU) Receives Average Rating of “Buy” from Brokerages
Veru Inc (NASDAQ:VERU) has been assigned an average rating of “Buy” from the five analysts that are covering the company, Marketbeat reports. Five analysts have rated the stock with a buy rating. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $5.50.
A number of equities research analysts recently issued reports on VERU shares. HC Wainwright set a $5.00 price objective on Veru and gave the company a “buy” rating in a research note on Thursday, September 13th. Zacks Investment Research upgraded Veru from a “sell” rating to a “buy” rating and set a $1.50 price objective on the stock in a research note on Wednesday, October 17th.
In other Veru news, insider K Gary Barnette purchased 100,000 shares of the stock in a transaction dated Tuesday, December 18th. The shares were bought at an average price of $1.46 per share, with a total value of $146,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Harry Fisch bought 30,000 shares of the stock in a transaction on Tuesday, December 18th. The shares were acquired at an average cost of $1.42 per share, for a total transaction of $42,600.00. The disclosure for this purchase can be found here. Insiders own 37.00% of the company’s stock.
Shares of NASDAQ:VERU traded down $0.04 during mid-day trading on Friday, reaching $1.40. The company had a trading volume of 55,800 shares, compared to its average volume of 87,366. The company has a current ratio of 0.83, a quick ratio of 0.66 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $92.36 million, a PE ratio of -3.59 and a beta of 0.85. Veru has a one year low of $1.17 and a one year high of $2.37.
Veru (NASDAQ:VERU) last issued its earnings results on Thursday, December 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.05). The firm had revenue of $5.20 million during the quarter, compared to the consensus estimate of $7.25 million. Veru had a negative net margin of 150.89% and a negative return on equity of 56.71%. Research analysts predict that Veru will post -0.23 earnings per share for the current year.
Veru Company Profile
Veru Inc operates as an oncology and urology biopharmaceutical company. The company operates through two segments, Commercial, and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation.
Featured Story: What are Closed-End Mutual Funds?
Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.